Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association

JJ Joseph, P Deedwania, T Acharya, D Aguilar… - Circulation, 2022 - Am Heart Assoc
Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …

Targeting early atherosclerosis: a focus on oxidative stress and inflammation

P Marchio, S Guerra-Ojeda, JM Vila… - Oxidative medicine …, 2019 - Wiley Online Library
Atherosclerosis is a chronic vascular inflammatory disease associated to oxidative stress
and endothelial dysfunction. Oxidation of low‐density lipoprotein (LDL) cholesterol is one of …

Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association

MJ Feinstein, PY Hsue, LA Benjamin, GS Bloomfield… - Circulation, 2019 - Am Heart Assoc
As early and effective antiretroviral therapy has become more widespread, HIV has
transitioned from a progressive, fatal disease to a chronic, manageable disease marked by …

Effects of icosapent ethyl on total ischemic events: from REDUCE-IT

DL Bhatt, PG Steg, M Miller, EA Brinton… - Journal of the American …, 2019 - jacc.org
Background: In time-to-first-event analyses, icosapent ethyl significantly reduced the risk of
ischemic events, including cardiovascular death, among patients with elevated triglycerides …

Lipoprotein (a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY …

M Szarek, VA Bittner, P Aylward… - European heart …, 2020 - academic.oup.com
Aims Lipoprotein (a) concentration is associated with first cardiovascular events in clinical
trials. It is unknown if this relationship holds for total (first and subsequent) events. In the …

Inhibition of interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS trial

BM Everett, JG MacFadyen, T Thuren, P Libby… - Journal of the American …, 2020 - jacc.org
Background Inflammation reduction with the interleukin (IL)-1β inhibitor canakinumab
significantly reduces the first major adverse cardiovascular event in patients with prior …

Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges

C Packard, MJ Chapman, M Sibartie, U Laufs… - Heart, 2021 - heart.bmj.com
Elevated levels of low-density lipoprotein cholesterol (LDL-C) are associated with increased
risk of coronary heart disease and stroke. Guidelines for the management of dyslipidaemia …

Myocardial infarction—From atherosclerosis to thrombosis: Uncovering new diagnostic and therapeutic approaches

J Palasubramaniam, X Wang… - … , thrombosis, and vascular …, 2019 - Am Heart Assoc
One of the earliest and best-recognized elements of atherosclerosis is its close relationship
with circulating LDL (low-density lipoprotein). There is convincing evidence that LDL …

[HTML][HTML] Emerging non-statin treatment options for lowering low-density lipoprotein cholesterol

C Bardolia, NS Amin, J Turgeon - Frontiers in cardiovascular …, 2021 - frontiersin.org
Low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for the development of
atherosclerotic cardiovascular disease. Statins have been the gold standard for managing …

[HTML][HTML] Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020

ОЛ Барбараш, ЮА Карпов, ВВ Кашталап… - Российский …, 2020 - cyberleninka.ru
АВК—антагонисты витамина К АГ—артериальная гипертония АД—артериальное
давление АСБ—атеросклеротическая бляшка АСК—ацетилсалициловая кислота …